Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Teva."

15 News Found

Teva confirms efficacy and safety of Ajovy for prevention of migraine
Clinical Trials | April 15, 2024

Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Clinical Trials | November 15, 2023

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India
News | April 20, 2023

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards

Merck KGaA appoints Global R&D Head & CSO for healthcare business sector
People | January 13, 2022

Merck KGaA appoints Global R&D Head & CSO for healthcare business sector

Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer

NATCO Pharma transfers Lenalidomide ANDA to Arrow
News | August 04, 2021

NATCO Pharma transfers Lenalidomide ANDA to Arrow

Arrow is the marketing partner in US

Latest Stories

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging